OUR PRODUCT

CNSA-001 is an oral formulation of synthetic sepiapterin, an endogenous naturally occurring pterin

RATIONAL

CNSA-001 is efficiently converted into tetrahydrobiopterin, a cofactor for critical cell-based enzymes

DEVELOPMENT

CNSA-001 is being developed to correct deficiencies in tetrahydrobiopterin dependent pathways

Developing Medicines to Improve the Lives of Patients with Debilitating Diseases

News

Censa Pharmaceuticals completes Phase I study and initiates enrollment into Phase II studies

WELLESLEY, MA – November 1st, 2018, Censa Pharmaceuticals Inc., a biopharmaceutical company focused on the development of CNSA-001 for orphan diseases, announced that it has successfully completed a Phase I study and has initiated enrollment into several Phase II studies. The Phase I study showed CNSA-001’s favorable safety profile and promising pharmacokinetic & pharmacodynamic characteristics. […]

Censa appoints new VP of Regulatory Affairs, Associate VP of Clinical Operations and Director of Quality

WELLESLEY, MA – July 19, 2018 – Censa Pharmaceuticals Inc. announced it has appointed Geoff Fatzinger PhD as Vice President of Regulatory Affairs, Michelle Skupien as Associate Vice President of Clinical Operations, and Eric Moore as Director or Quality. Geoff joined Censa with 15+ years’ experience in regulatory affairs. Prior to joining the Censa team […]

Retrophin and Censa Pharmaceuticals Enter into Strategic Collaboration to Advance CNSA-001 for the Treatment of Phenylketonuria (PKU)

SAN DIEGO, Jan. 05, 2018 (GLOBE NEWSWIRE) — Retrophin, Inc. (NASDAQ:RTRX) today announced a joint development agreement with Censa Pharmaceuticals, a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate CNSA-001 for the treatment of phenylketonuria (PKU). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin (BH4) […]